

**Patient Information**

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Sex:  Male  Female SSN: \_\_\_\_\_ Wt (kg/lbs): \_\_\_\_\_ Ht (cm/in): \_\_\_\_\_  
 Address: \_\_\_\_\_ Phone: \_\_\_\_\_ Alternate: \_\_\_\_\_  
 Caregiver Name: \_\_\_\_\_ Relation to Patient: \_\_\_\_\_ Phone: \_\_\_\_\_  
 Insurance Plan: \_\_\_\_\_ Plan ID: \_\_\_\_\_ BIN #: \_\_\_\_\_ PCN #: \_\_\_\_\_ GRP #: \_\_\_\_\_

Please fax a copy of the front and back of the insurance card(s).

**Prescriber + Shipping Information**

Prescriber Name: \_\_\_\_\_ DEA: \_\_\_\_\_ NPI: \_\_\_\_\_  
 Address: \_\_\_\_\_  
 Phone: \_\_\_\_\_ Alternate: \_\_\_\_\_ Fax: \_\_\_\_\_ Email: \_\_\_\_\_  
 If shipping to prescriber:  First Fill  Always  Never

**Clinical Information (Please fax all pertinent clinical and lab information)**

**Diagnosis:**  L40.0 (Psoriasis vulgaris)  L40.8 (Other psoriasis)  L40.9 (Psoriasis, unspecified)  L40.5 (Psoriatic arthritis)  L73.2 (Hidradenitis Suppurativa)  \_\_\_\_\_  
 Diagnosis Date: \_\_\_\_\_ TB Test:  Yes  No Neg. Test Date: \_\_\_\_\_ HBV:  Yes  No If yes, currently treated:  Yes  No  
 BSA affected (%): \_\_\_\_\_ Affected areas:  Palms  Soles  Head  Neck  Genitalia  \_\_\_\_\_  
 Prior Therapy  Yes  No \_\_\_\_\_  
 Reason for Discontinuation of Therapy \_\_\_\_\_  
 Approximate Start Date \_\_\_\_\_ Approximate End Date \_\_\_\_\_  
 Comorbidities: \_\_\_\_\_  
 Concomitant Medications: \_\_\_\_\_  
 Allergies:  NKDA  Other: \_\_\_\_\_

Prescription	Directions	Quantity	Form	Refill
<input type="checkbox"/> <b>Inflectra®</b> (infliximab)	<input type="checkbox"/> Infuse 5 mg/kg at weeks 0 and 2 <input type="checkbox"/> Infuse 5 mg/kg at week 6 and then every 8 weeks thereafter	<input type="checkbox"/> 100 mg	<input type="checkbox"/> Vials	0
<input type="checkbox"/> <b>Otezla®</b> (apremilast)	<input type="checkbox"/> Take as directed per package instructions <input type="checkbox"/> Prescriber provided patient with 2 week starter pack sample on date _____ <input type="checkbox"/> Take 30 mg twice daily by mouth <input type="checkbox"/> _____	<input type="checkbox"/> 55 tablets <input type="checkbox"/> 60 x 30 mg tablets <input type="checkbox"/> _____	<input type="checkbox"/> 28-day starter pack	0
<input type="checkbox"/> <b>Picato®</b> (ingenol mebutate)	<input type="checkbox"/> Apply 1 tube per day for 3 consecutive days <input type="checkbox"/> Apply 1 tube per day for 2 consecutive days	<input type="checkbox"/> _____ x 0.015% (face/scalp tx) <input type="checkbox"/> _____ x 0.05% (body tx)	<input type="checkbox"/> Gel	
<input type="checkbox"/> <b>Remicade®</b> (infliximab)	<input type="checkbox"/> Infuse 5 mg/kg intravenously at weeks 0 and 2 <input type="checkbox"/> Infuse 5 mg/kg at week 6 and then every 8 weeks thereafter	<input type="checkbox"/> 100 mg	<input type="checkbox"/> Vials	0
<input type="checkbox"/> <b>Simponi®</b> <i>Psoriatic Arthritis</i> (golimumab)	<input type="checkbox"/> Inject 50 mg subq once a month	<input type="checkbox"/> 1 x 50 mg/0.5mL	<input type="checkbox"/> SmartJect® Autoinjector <input type="checkbox"/> PFS	
<input type="checkbox"/> <b>Sivextro®</b> (tedizolid phosphate)	<input type="checkbox"/> Inject 200 mg IV once daily for 6 days <input type="checkbox"/> Take 1 tablet by mouth daily for 6 days	<input type="checkbox"/> 6 x 200mg	<input type="checkbox"/> IV <input type="checkbox"/> Tablet	
<input type="checkbox"/> <b>Stelara®</b> (ustekinumab)	<input type="checkbox"/> Inject 45 mg subq on Day 1 (≤100 kg) <input type="checkbox"/> Inject 90 mg subq on Day 1 (>100 kg) <input type="checkbox"/> Inject 45 mg subq on Day 29 and every 12 weeks thereafter (≤100 kg) <input type="checkbox"/> Inject 90 mg subq on Day 29 and every 12 weeks thereafter (>100 kg) Patient eligible for self-administration: <input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> 1 x 45 mg/0.5mL <input type="checkbox"/> 1 x 90 mg/mL <input type="checkbox"/> 1 x 45 mg/0.5mL <input type="checkbox"/> 1 x 90 mg/mL	<input type="checkbox"/> PFS <input type="checkbox"/> PFS	0
<input type="checkbox"/> <b>Taltz®</b> (Ixekizumab)	<input type="checkbox"/> Weeks 0 - 2: Inject 160 mg (2 x 80 mg) subq at week 0, then inject 80 mg subq at week 2 <input type="checkbox"/> Weeks 4 - 10: Inject 80 mg subq at week 4 and every two weeks thereafter through week 10 <input type="checkbox"/> Week 12 onwards: Inject 80 mg subq at week 12 and every four weeks thereafter	<input type="checkbox"/> 3 x 80 mg/mL <input type="checkbox"/> 2 x 80 mg/mL <input type="checkbox"/> 1 x 80 mg/mL	<input type="checkbox"/> Autoinjectors <input type="checkbox"/> PFS <input type="checkbox"/> Autoinjectors <input type="checkbox"/> PFS <input type="checkbox"/> Autoinjectors <input type="checkbox"/> PFS	0 1
<input type="checkbox"/> <b>Tremfya®</b> (guselkumab)	<input type="checkbox"/> Inject 100 mg subq at weeks 0 and 4 <input type="checkbox"/> Inject 100 mg subq every 8 weeks	<input type="checkbox"/> 2 x 100 mg <input type="checkbox"/> 1 x 100 mg	<input type="checkbox"/> PFS	0
<input type="checkbox"/> <b>Zyvox®</b> (linezolid)	<input type="checkbox"/> Inject 600 mg IV twice a day <input type="checkbox"/> Take 1 tablet by mouth twice daily	<input type="checkbox"/> _____ x 600 mg	<input type="checkbox"/> IV <input type="checkbox"/> Tablets	

Injection training provided by:  Physician's Office  Pharmacy  Other: \_\_\_\_\_  
 Per state-specific law, prescriptions will be dispensed as generic, if applicable, unless notated otherwise:

Prescriber's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

I authorize AmeriPharma and its representatives to act as an agent to initiate and execute the insurance prior authorization process for this prescription and any future fills of the same prescription for the patient listed above. I understand that I can revoke this designation at any time by providing written notice to AmeriPharma.

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately by calling 877-778-0318 to obtain instructions as to the proper destruction of the transmitted material. Thank you.